



Company Name: Linical Co., Ltd.
Representative: Kazuhiro Hatano
President & CEO
(TSE code: 2183)

11 April 2019

Linical Co., Ltd. announces that LINICAL Europe Holding GmbH established an affiliate company in Hungary

Linical Co., Ltd. (hereinafter referred to as "Linical") hereby announces that our fully owned European subsidiary, LINICAL Europe Holding GmbH established a wholly owned subsidiary in Hungary as a result of re-organization of LINICAL Europe GmbH Hungary branch office described below;

1. Purpose of the establishment

Linical group, a global clinical development partner, is expanding its network and business overseas (i.e. the U.S., Europe, Asia) to further strengthen its capability of delivering a one-stop comprehensive service to meet the needs for and increasing demands of multinational clinical trials from clients.

This status change of the entity in Hungary increases our focus on the European market, and supports our rapidly growing client needs.

2. Overview of the Subsidiary

1) Company name	Linical Hungary Korlátolt Felelősségű Társaság (Linical Hungary Kft.)
2) Address	Bojtár utca 39,1037 Budapest, Hungary
3) Representative officer	Keigo Tsujimoto, Rafael Romero Jimenez
4) Main business lines	CRO business
5) Capital	3,000,000 HUF (JPY 1,170,000*)
6) Establishment date	26 March 2019
7) Ownership ratio	100% owned by LINICAL Europe Holding GmbH

*: Calculated on the basis of 1HUF=0.39JPY (Inter-bank rate as of 10 Apr 2019)

3. Overview of LINICAL Europe Holding GmbH

1) Company name	LINICAL Europe Holding GmbH
2) Address	Hahnstraße 40, 60528 Frankfurt am Main, Germany
3) Representative officer	Keigo Tsujimoto, Rafael Romero Jimenez
4) Main business lines	Holding company
5) Capital	25,000 EUR (JPY 3,130,000*)

*: Calculated on the basis of 1EUR=125.20JPY (Inter-bank rate as of 10 Apr 2019)

4. Future outlook

The establishment of the subsidiary will have no significant effect on the consolidated operating results of Linical Co., Ltd. for the fiscal year ending 31 March 2019.

END

Notes: This is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.